NVO Stock Today, February 04: Shares Plunge on 2026 Sales Cut

Novo Nordisk stock dropped sharply today after management cut 2026 revenue guidance by 5–13%, citing strong U.S. pricing pressure, planned Wegovy price cuts, patent headwinds for semaglutide, and tougher competition. The ADR NVO fell heavily intraday as investors reset GLP-1 profit expectations. A DKK 15 billion buyback did not steady sentiment. We explain the drivers, the price action, and what this means for German portfolios, with practical levels and next catalysts to watch.

Why guidance shocked the market

Management cut 2026 revenue guidance by 5–13%, pointing to softer U.S. net pricing and mix. That range implies a meaningful reset to medium-term growth for obesity and diabetes franchises. For a stock priced for steady GLP-1 expansion, the shift surprised the market. The update landed on 4 February alongside a DKK 15 billion buyback. source

The company flagged stronger rebate demands from U.S. payers, expected Wegovy price cuts to expand access, and rising Ozempic competition. Patent expiries for semaglutide later in the decade raise longer-term questions on durability. The mix of lower list prices and rebate pressure weighed on 2026 visibility, which explains the swift valuation reset in Novo Nordisk stock today.

The selloff pulled broader pharma lower in Europe, with risk spreading to GLP-1 suppliers and healthcare funds. German investors saw sentiment weaken across peers as pricing fears rose. Local sector ETFs and Frankfurt listings with U.S. exposure softened. The market focus is now on how far U.S. rebates go and how quickly volumes can offset lower net prices. source

What the price action signals

Novo Nordisk stock saw a sharp gap lower, with the ADR trading beneath its 50-day and 200-day moving averages at 53.22 and 58.84. Intraday levels near 49.10 high and 47.13 low define the first resistance and support zone. A close below the 51.90 mid Bollinger line keeps bears in control near term.

Turnover spiked to 34.39 million shares versus a 23.06 million average, confirming strong supply. Average true range at 1.79 shows wider daily swings. Bollinger lower band sits near 45.37, a level many short-term traders will watch. Until volume dries up on down days, rallies may meet selling pressure.

Active traders can watch 49.10 as first resistance, then the 50-day at 53.22. Support sits at 47.13, then the 45.37 band. Tight stops matter given wide ranges. For long-only investors in Germany, staged entries reduce timing risk. Novo Nordisk stock likely needs fresh data on pricing and volumes before a durable base forms.

GLP-1 battle: competition and policy risks

Eli Lilly remains the key competitor, and Ozempic competition has intensified as payers push harder on price. If rivals trade price for volume, net prices can fall faster than expected. Novo Nordisk stock now discounts a tougher share and margin outlook, until we see proof that volume growth offsets lower pricing.

Management cited patent expiries for semaglutide later this decade, which raises questions on long-term exclusivity economics. While biosimilar timelines are uncertain, investors typically de-rate margins as protection wanes. The new guidance bakes in pressure earlier, which is why 2026 revenue guidance shook confidence today.

The U.S. market is central to profits, and payer scrutiny is rising as obesity drugs scale. Expanded access often comes with steeper rebates, step therapy, or outcomes contracts. Until contracts stabilize, Novo Nordisk stock will trade on headlines about rebates, Medicare policy signals, and employer coverage dynamics across GLP-1 plans.

What it means for German portfolios

After the drop, the stock trades near a 13.6 P/E and roughly 4.5 times sales based on recent data, with a dividend yield around 2.4%. Liquidity is strong, but the current ratio near 0.78 and higher capex needs reduce flexibility. The cut to 2026 revenue guidance argues for a lower premium while uncertainty stays high.

We prefer staggered buys to manage volatility. Keep position sizes modest until we see stability in U.S. net pricing and clear signs that Wegovy price cuts drive volume without crushing margins. Use stop-loss rules and avoid averaging down quickly. Novo Nordisk stock remains quality, but the earnings path is now bumpier.

Watch for contract updates with U.S. payers, European reimbursement changes, and competitor launches from Eli Lilly. The DKK 15 billion buyback offers some downside support if executed steadily. Monitor production scale-up, obesity prescription trends, and any changes to patient access rules that could reshape 2026 revenue guidance again.

Final Thoughts

Novo Nordisk stock fell because the path to 2026 looks tougher. Management now expects 5–13% lower revenue than previously planned, as U.S. rebates rise, Wegovy price cuts expand access at lower net pricing, and competition stiffens. For German investors, the key is to separate a quality franchise from a reset in near-term economics. Focus on three items: contract stability with U.S. payers, volume growth in obesity care, and cost discipline to defend margins. Consider staged entries, defined risk, and a long view on GLP-1 demand. Confirmation that volumes offset lower prices would be the clearest green light for adding exposure.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.